Our findings support <i>MFAP2</i> as a candidate prognostic biomarker and a potential therapeutic target; however, additional validation in larger molecularly annotated clinical cohorts and multiple GBM models is warranted. This evidence concerns the gene MFAP2 and glioblastoma.